These data suggest that maintenance with EGFR TKIs after first line chemotherapy is a good treatment strategy in unselected patients with advanced NSCLC, and an excellent option for patients with EGFR mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.